Zepbound (Tirzepatide) for Weight Loss: A Houston Patient Guide

Zepbound (tirzepatide) is a once-weekly injectable medication by Eli Lilly, FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related health condition. It is the same molecule as Mounjaro but marketed and covered under the obesity/weight management indication rather than the diabetes indication.

In the SURMOUNT-1 trial, adults without diabetes lost an average of 20.9% of body weight on the 15 mg dose — roughly 48 pounds for a 230-pound person. About 1 in 3 patients lost 25% or more. This is the most powerful weight loss result ever demonstrated by a medication in a clinical trial. Results at lower doses were also impressive: 17.8% at 10 mg and 15% at 5 mg.

In direct comparison studies, tirzepatide (Zepbound) produced greater weight loss than semaglutide (Wegovy) at equivalent time points. The SURMOUNT-5 trial showed tirzepatide achieved approximately 47% more weight loss than semaglutide at 72 weeks. Both are excellent medications — the best choice depends on your individual health history, side effect profile, insurance coverage, and cost. Your endocrinologist can help you decide.

Zepbound and Mounjaro contain the exact same drug — tirzepatide — made by Eli Lilly. The difference is only in FDA-approved indication and insurance billing: Mounjaro uses Type 2 diabetes coverage, Zepbound uses obesity/weight management coverage. If you have Type 2 diabetes, your endocrinologist may prescribe Mounjaro. If your main goal is weight management without a diabetes diagnosis, Zepbound is the right version for insurance purposes.

The most common side effects are nausea, diarrhea, vomiting, and constipation — most pronounced during dose escalation and typically improving over several weeks. In SURMOUNT trials, about 5–10% of patients stopped the medication due to GI side effects. Rare serious risks include pancreatitis, gallbladder problems, elevated heart rate, and a theoretical thyroid tumor risk based on animal data. Your endocrinologist reviews your complete history before prescribing.

Coverage for Zepbound is expanding but still inconsistent across plans. Some commercial insurers cover it for obesity with documented prior weight loss attempts and related comorbidities. Many Medicare plans do not currently cover weight loss medications, though this is an active policy area. Prior authorization is almost universally required. Our team verifies your coverage and assists with the prior authorization process.

Yes — if you have Type 2 diabetes and obesity, tirzepatide is an excellent option. However, your endocrinologist may prescribe it as Mounjaro (same drug) since that has the diabetes-specific labeling and may have better insurance coverage through your diabetes benefit. The clinical effect is identical. We'll help navigate which version is best covered for your specific situation.

Zepbound is a long-term medication for chronic weight management. Clinical trials show that when Zepbound is stopped, most patients regain a significant portion of their lost weight within 12 months. Like blood pressure medication or cholesterol medication, it's designed to be taken ongoing. Your endocrinologist will discuss your long-term plan, including what happens if you need to pause due to cost, side effects, or surgery.